vTv Therapeutics Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting a net loss of $7.1 million for the quarter and $27.0 million for the year. The company also announced a $20.0 million payment received in February 2026 from an amended licensing agreement with Newsoara Biopharma Inc. and projected completion of enrollment in its CATT1 Phase 3 trial in the third quarter of 2026.
Key takeaways
Net loss attributable to vTv shareholders was $7.1 million, or $0.58 per basic share, for the three months ended December 31, 2025.
Cash and cash equivalents increased to $88.9 million as of December 31, 2025, compared to $36.7 million as of December 31, 2024.
The company received a $20.0 million upfront payment in February 2026 from Newsoara Biopharma Inc. under an amended licensing agreement for HPP737.
Enrollment in the CATT1 Phase 3 trial for cadisegliatin is expected to be completed in the third quarter of 2026.
Full year 2025 R&D expenses increased to $17.9 million from $11.5 million in 2024, driven by higher spending on cadisegliatin clinical studies.